Other RGD-containing peptides, such as iRGD (amino acid sequence: CRGDK/RGPD/EC), could also target cancer cells through binding to neuropilin-1 (NRP-1) receptors expressed in tumor and vascular tissues (Liu et al., 2021b). The gene discussed is NRP1; the disease is cancer.